Indeed, several CSPG4-specific CARs have been generated by utilizing monoclonal antibodies (mAbs) reactive against CSPG4 and pre-clinically demonstrated anti-tumor activity against not only melanoma, but also against many other CSPG4-positive cancer histotypes, including breast carcinoma, head and neck squamous cell carcinoma and mesothelioma, as well as against CIC [85–88]. This evidence concerns the gene CSPG4 and neoplasm.